IN
INBS.US Intelligent Bio Solutions Inc.
- Market cap
- USD 5.84M
- P/E
- -
- P/B
- 1.06x
- ROE
- -140.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is INBS.US undervalued?
Graham numberThe Graham number of Intelligent Bio Solutions Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intelligent Bio Solutions Inc. fundamental analysis
No fundamental analysis for Intelligent Bio Solutions Inc. yet.
Intelligent Bio Solutions Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutio…
Full company profileIntelligent Bio Solutions Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Intelligent Bio Solutions Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 189K | 1.98M | 0.00 | 1.26M | 3.11M | 3.05M | 4.22M | 5.57M |
| Gross Profit | - | - | - | 189K | 1.98M | 0.00 | 327K | 1.43M | 1.25M | 2.05M | 2.08M |
| Operating Income | -173K | -4.60M | -6.73M | -2.71M | -5.57M | -8.34M | -12.6M | -10.3M | -10.6M | -12.6M | -10.7M |
| EBITDA | 15.7K | 467.00 | -6.67M | -2.56M | -1.82M | -8.30M | -9.47M | -8.81M | -9.21M | -11.3M | -9.78M |
| Net Income | -340K | -5.02M | -7.34M | -3.71M | -7.04M | -8.31M | -10.6M | -10.2M | -10.6M | -12.4M | -10.6M |
| EPS | -5.63 | -83 | -121 | -52 | -135 | -0.57 | -53 | -32 | -20 | -8.44 | -3.44 |
| Balance Sheet | |||||||||||
| Total Assets | 667K | 2.50M | 2.33M | 2.48M | 21.9M | 12.4M | 10.4M | 13.8M | 8.25M | 11.9M | 13.6M |
| Total Liabilities | 6.58M | 5.56M | 6.31M | 7.69M | 6.85M | 5.81M | 6.67M | 5.60M | 5.44M | 6.65M | 6.27M |
| Shareholders' Equity | -5.91M | -4.38M | -4.62M | -5.19M | 15.1M | 6.55M | 3.80M | 8.33M | 3.00M | 5.51M | 7.58M |
| Cash & Short-term Investments | 56.0K | 418K | 198K | 427K | 12.6M | 8.24M | 1.54M | 6.30M | 1.02M | 3.99M | 5.93M |
| Total Debt | 3.53M | 4.84M | 5.13M | 5.13M | - | - | 1.92M | 1.15M | 282K | 1.82M | 1.79M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -244K | -5.38M | -5.58M | -499K | -11.3M | -3.36M | -7.38M | -9.57M | -9.68M | -11.9M | -11.0M |
| Capital Expenditure | 0.00 | 0.00 | 380K | 380K | 3.00 | 380K | 505K | 221K | 232K | 126K | 0.00 |
| Free Cash Flow | -244K | -5.38M | -5.58M | -499K | -11.3M | -3.74M | -7.88M | -9.79M | -9.91M | -12.1M | -11.0M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -46.7% | -126.9% | -279.9% | -121.9% | -352.7% | -225.6% | -140.2% |
| ROA | -51.0% | -201.1% | -315.2% | -150.0% | -32.2% | -67.2% | -102.7% | -73.7% | -128.1% | -104.1% | -78.1% |
| Net Profit Margin | - | - | - | -1,967.8% | -355.3% | - | -845.9% | -326.4% | -346.2% | -294.9% | -191.0% |
| Debt to Equity | - | - | - | - | - | - | 0.50x | 0.14x | 0.09x | 0.33x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Intelligent Bio Solutions Inc. dividends
Intelligent Bio Solutions Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 16, 2025.
Who owns Intelligent Bio Solutions Inc.
- Insiders 2.74%
- Institutions 5.77%
- Public & others 91.49%
- Shares outstanding 3.32M
- Free float 3.22M
Top funds holding INBS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 12.5K | 0.38% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.54K | 0.08% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 1.77K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 409.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding INBS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 141K | 4.26% | +8.77% | Jun 2026 |
| Geode Capital Management, LLC | 20.8K | 0.63% | -27.16% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.81K | 0.18% | 0.00% | Jun 2026 |
| UBS Group AG | 5.74K | 0.17% | +1,441.67% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.96K | 0.12% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.28K | 0.10% | +162.40% | Jun 2026 |
| Advisor Group Holdings, Inc. | 200.00 | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 142.00 | 0.00% | 0.00% | Jun 2026 |
| CURIO WEALTH, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 0.00 | 0.00% | -100.00% | Jun 2026 |
Intelligent Bio Solutions Inc. company profile
- Company name
- Intelligent Bio Solutions Inc.
- Ticker
- INBS.US
- Exchange
- USA Stocks
- Listed since
- Dec 23, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 59
- Fiscal year end
- June
- Address
- 135 West, 41st Street, New York, NY, United States, 10036
- Phone
- 646 828 8258
- Website
- ibs.inc
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Intelligent Bio Solutions Inc. management
7- Mr. Harry SimeonidisPresident & CEO · born 1967
- Mr. Spiro Kevin Sakiris B.Bus, C.A., Dip LawChief Financial Officer · born 1962
- Mr. Callistus SequeiraVice President of Global Quality & Operations
- Mr. Doug HeathVice President of Global Sales
- Anna TurkingtonVice President of Marketing
- Mr. Valter PintoManaging Director of KCSA Strategic Communications
- Mr. Peter PassarisVice President of Product Development